EUVIMEDEUVIMED entdecken
Crossref

Clinical Characteristics, Genotypes, and Treatment Outcomes in 133 Patients With Spinal Muscular Atrophy: A Retrospective Cohort

Siyi Gan iD, Li Xu, Haiyan Yang, Liwen Wu

Acta Paediatrica · 2025

DOI: 10.1111/apa.70263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Paediatrica, 2025. Verfasst von Siyi Gan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Hunan Children's Hospital, Children's Hospital, Xiangya Medical School, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Survival of Motor Neuron 1 Protein, Oligonucleotides, Muscular Atrophy, Spinal, Spinal Muscular Atrophies of Childhood. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To characterise spinal muscular atrophy (SMA) phenotypes, genetic profiles, and nusinersen efficacy in China.

Methods

In 133 SMA patients (age 6.38 ± 3.66 years), SMN1 mutations and SMN2 copy numbers were analysed by MLPA and sequencing. Motor function was longitudinally assessed using subtype‐specific scales (CHOP‐INTEND/HFMSE/RULM/6MWT) at baseline, 6, and 12 months post‐nusinersen.

Results

Cohort distribution: type I 31.6% (42/133), II 42.1% (56/133), III 26.3% (35/133). Genetic profiling identified: SMN1 exon7 + 8 deletions (81.2%, 108/133); exon7‐only deletions (15.0%, 20/133); and a novel c.884A>T; c.22dup mutation (0.8%). SMN2 copy number inversely correlated with clinical severity ( p < 0.001). At 12 months, type I patients showed CHOP‐INTEND improvement from 22.0 ± 10.7 to 34.4 ± 14.9 (Δ12.4 ± 8.7; all Δ ≥ 5); type II demonstrated HFMSE Δ3.6 ± 3.4 and RULM Δ3.4 ± 2.1 (1 ambulation milestone); type III exhibited 6MWT gains of 48.8 ± 35.1 m (Δrange 6.0–119.8) with concurrent RULM/HFMSE improvements.

Conclusions

Nusinersen elicited clinically significant motor improvements across SMA subtypes, demonstrating the strongest functional gains in type I (56.4% CHOP‐INTEND improvement). We report for the first time a rare case of SMN1 compound heterozygous double‐site mutations (c.884A>T; c.22dup).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Survival of Motor Neuron 1 ProteinOligonucleotidesMuscular Atrophy, SpinalSpinal Muscular Atrophies of ChildhoodHumansMaleFemaleChildRetrospective StudiesChild, PreschoolSurvival of Motor Neuron 2 ProteinInfantTreatment OutcomeGenotypeAdolescentMutationChina

Stichwörter der Autor:innen

double‐site mutationsnusinersenspinal muscular atrophysurvival motor neuron

Substanzen

nusinersenSurvival of Motor Neuron 1 ProteinOligonucleotidesSurvival of Motor Neuron 2 ProteinSMN1 protein, humanSMN2 protein, human

Autor:innen und Institutionen

  • Neurology Department, Hunan Children's Hospital, Children's Hospital, Xiangya Medical School, Central South University, Changsha, China.

ORCID-Profile: Siyi Gan

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Gan, S., Xu, L., Yang, H., & Wu, L. (2025). Clinical Characteristics, Genotypes, and Treatment Outcomes in 133 Patients With Spinal Muscular Atrophy: A Retrospective Cohort. Acta Paediatrica. https://doi.org/10.1111/apa.70263

Vancouver

Gan S, Xu L, Yang H, Wu L. Clinical Characteristics, Genotypes, and Treatment Outcomes in 133 Patients With Spinal Muscular Atrophy: A Retrospective Cohort. Acta Paediatrica. 2025. doi:10.1111/apa.70263

BibTeX
@article{Gan2025,
  author = {Gan, Siyi and Xu, Li and Yang, Haiyan and Wu, Liwen},
  title = {Clinical Characteristics, Genotypes, and Treatment Outcomes in 133 Patients With Spinal Muscular Atrophy: A Retrospective Cohort},
  journal = {Acta Paediatrica},
  year = {2025},
  doi = {10.1111/apa.70263}
}
Kostenlos starten →